Anantharaman Vathsala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anantharaman Vathsala has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Concesa B. Cabanayan Casasola
1 shared publicationDavid Machin
1 shared publicationEnrique T. Ona
1 shared publicationGilbert S.C. Chiang
1 shared publicationH.X. Lou
Department of Pharmacy, Singapore General Hospital, Singapore
1 shared publicationHuei-Xin Lou
1 shared publication
Latest Publications
- 24 November 2006
- Published by Wiley
- p. 593-603
Renal Transplantation
- 27 September 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (6) , 765-774
Randomized Trial of Alemtuzumab for Prevention of Graft Rejection and Preservation of Renal Function after Kidney Transplantation1
A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n=20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n=10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, −92 to −34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%–97%) were steroid free. These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx.
- 27 September 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (6) , 765-774
Randomized Trial of Alemtuzumab for Prevention of Graft Rejection and Preservation of Renal Function after Kidney Transplantation1
A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n=20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n=10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, −92 to −34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%–97%) were steroid free. These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx.
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 2090-2091
Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 2090-2091
Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 1868-1870
Immunosuppression use in renal transplantation from Asian transplant centers: A preliminary report from the Asian Transplant Registry
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 1868-1870
Immunosuppression use in renal transplantation from Asian transplant centers: A preliminary report from the Asian Transplant Registry
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 1873-1875
Improving cadaveric organ donation rates in kidney and liver transplantation in Asia
- 1 September 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 1873-1875
Improving cadaveric organ donation rates in kidney and liver transplantation in Asia